Skip to main content

Table 3 CEP17 status according to HER2 and TOP2A gene copy number and amplification status

From: Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic Cooperative Oncology Group (HeCOG) phase III trials

 

CEP17 status

 
 

No gain

Gain

 
 

N (%)

N (%)

p

HER2 gene copies

  

<0.001

    ≤4

506 (68.2)

236 (31.8)

 

    4-6

10 (15.4)

55 (84.6)

 

    >6

104 (46.4)

120 (53.6)

 

TOP2A gene copies

  

<0.001

    ≤4

587 (67.1)

288 (32.9)

 

    4-6

13 (16.9)

64 (83.1)

 

    >6

20 (25.3)

59 (74.7)

 

HER2 gene status

  

<0.001

    Non-amplified

500 (63.5)

287 (36.5)

 

    Amplified

120 (49.2)

124 (50.8)

 

TOP2A gene status

  

<0.001

    Deleted

18 (34.6)

34 (65.4)

 

    Non-amplified

558 (63.8)

317 (36.2)

 

    Amplified

44 (42.3)

60 (57.7)

 
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us